Sana Biotechnology (SANA) Fundamentals 2026 — Revenue Analysis | SniperIQ
Sana Biotechnology (SANA) is a US-listed Healthcare company in Biotechnology with a market capitalization of $871M, trading at
Sana Biotechnology (SANA) has a market capitalization of approximately $871M, trading at
Sana Biotechnology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Sana Biotechnology runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Sana Biotechnology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Sana Biotechnology carries a debt-to-equity ratio of 0.63x and a current ratio of 1.29x, with a market beta of 2.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sana Biotechnology (SANA) the key facts are: market cap $871M, 52-week range 2.61-6.55. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get Sana Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.